W
William W. Busse
Researcher at University of Wisconsin-Madison
Publications - 740
Citations - 62685
William W. Busse is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Asthma & Eosinophil. The author has an hindex of 115, co-authored 697 publications receiving 56703 citations. Previous affiliations of William W. Busse include National Institutes of Health & University at Buffalo.
Papers
More filters
Journal ArticleDOI
Mechanisms of acute eosinophilic inflammation in a case of acute eosinophilic pneumonia in a 14-year-old girl
Véronique Godding,Eddy Bodart,Monique Delos,Yves Sibille,Laurence Galanti,Patrick De Coster,Nizar N. Jarjour,William W. Busse +7 more
TL;DR: Acute eosinophilic pneumonia (AEP) is characterized by respiratory distress, eosInophilic infiltration in the lung, acute onset, resolution of symptoms with corticosteroids and the absence of relapse.
Journal ArticleDOI
Effects of the very late adhesion molecule 4 antagonist WAY103 on human peripheral blood eosinophil vascular cell adhesion molecule 1–dependent functions
TL;DR: Although small-molecule VLA-4 antagonists, such as WAY103, might reduce eosinophil adhesion, this approach might not be sufficient to eliminate this cell from in vivo allergic airway inflammatory participation and could even promote specific cell activation.
Journal ArticleDOI
Asthma: diagnosis and management.
TL;DR: In the coming years, it is expected that additional testing modalities will be available for more precise monitoring of asthma control, and an increased understanding of pharmacogenetics will enable the tailoring of asthma medications to specific patients, providing customized therapy to maximize asthma control.
Journal ArticleDOI
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial
Daniel J. Jackson,Leonard B. Bacharier,Peter J. Gergen,Lisa Gagalis,Agustin Calatroni,Stephanie Wellford,Michelle A. Gill,Jeffrey R. Stokes,Andrew H. Liu,Rebecca S. Gruchalla,Robyn T. Cohen,Melanie M. Makhija,Gurjit K. Khurana Hershey,George T. O'Connor,Jacqueline A. Pongracic,Michael Sherenian,Katherine Rivera-Spoljaric,Edward M. Zoratti,Stephen J. Teach,Meyer Kattan,Cullen M. Dutmer,Hae-Sung Kim,Carin I. Lamm,William J. Sheehan,R. Max Segnitz,Kimberly A. Dill-McFarland,Cynthia M. Visness,Patrice M. Becker,James E. Gern,Christine A. Sorkness,William W. Busse,Matthew C. Altman +31 more
TL;DR: Phenotype-directed therapy with mepolizumab in urban children with exacerbation-prone eosinophilic asthma reduced the number of exacerbations.
Journal ArticleDOI
Reducing Exacerbations in the Inner City: Lessons from the Inner-City Asthma Consortium (ICAC)
TL;DR: The Inner-City Asthma Consortium was established in the early 1990s to identify risk factors for and to evaluate treatments to reduce asthma symptoms and exacerbations, and therapy directed at reducing the role of allergy was evaluated.